clinical trial · NCT07753850
A Phase 2 Study of SL-325 in Crohn's Disease Patients
Crohn's DiseaseSL-325Placebo
brief summary
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
started
Oct 1, 2026
primary completion
Jul 1, 2028
completion
Jun 1, 2030
last updated
Aug 10, 2026
official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol